Translating Research into Therapies
نویسندگان
چکیده
The human body is more than the sum of its organs. Yet for hundredsof years,medicine andmedical research have divvied up the totality of the person into diseases that are organ specific and characterized largely by their phenotypic presentation. These divisions are also reflected in the organization of academic medical centers and pharmaceutical research and development and even permeate the funding of biomedical research, with diseasecenteredNIH institutesandprivate foundations. This is understandable, and I am not suggesting that it should be eliminated because it is still a critical structure for delivering patient care. But in research, our understanding of the functioning of the body and the causes of disease has progressed beyond the phenotypic, and I would argue that the present structure has led to the curtaining off of one organ or disease from its brethren. An individual is the sum of their medical history, and having one disease can greatly alter the likelihood of having another. We know now that chronic inflammation also increasescancer risk (e.g., ulcerativecolitis and colorectal cancer) and is also a risk factor for obesity and neurodegeneration. These comorbidities can be explained in terms of common cellular and molecular pathways. We need to think of new ways to organize research into hubs informed by common themes—for example, the agingprocess or geneticmedicine—where physician scientists and basic researchers from different traditional disciplines can come together. In this way, we can begin to see behind the curtain that divides one branch of knowledge from another. Progress through Partnership
منابع مشابه
Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis
Targeted therapies including tumour necrosis factor α (TNFα) inhibitors have trans‐ formed the management of a number of autoimmune conditions over the past 20 years. One autoimmune rheumatological condition with significant potential for the develop‐ ment of targeted therapies is systemic sclerosis (SSc). In this chapter, we use SSc as an example of how research into the pathogenic processes u...
متن کاملTranslating the molecular hallmarks of colorectal cancer to patient therapies: an interview with Owen Sansom
937 Owen Sansom, Deputy Director of the Cancer Research UK Beatson Institute, began his research career investigating the molecular mechanisms of apoptosis. Over the course of his work he has moved progressively into a more translational arena, and the current focus of his lab is to understand the signalling pathways underlying colorectal and pancreatic cancers. The Sansom lab uses mouse models...
متن کاملNorms of Translating Taboo Words and Concepts from English into Persian after the Islamic Revolution in Iran
The research attempted to discover the norms of translating taboo words and concepts after the Islamic Revolution in Iran using Toury’s (1995) framework for classification of norms. The corpus of the study composed of Coelho’s novels between 1990 and 2005 and their Persian translations which were prepared and analyzed manually to discover the norms. During both the selection of novels for trans...
متن کاملTranslating cancer genomes and transcriptomes for precision oncology.
Understanding the molecular landscape of cancer has facilitated the development of diagnostic, prognostic, and predictive biomarkers for clinical oncology. Developments in next-generation DNA sequencing technologies have increased the speed and reduced the cost of sequencing the nucleic acids of cancer cells. This has unlocked opportunities to characterize the genomic and transcriptomic landsca...
متن کاملESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies
Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory ha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Cell
دوره 148 شماره
صفحات -
تاریخ انتشار 2012